16,769 Shares in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Acquired by Raymond James Financial Inc.

Raymond James Financial Inc. acquired a new stake in IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 16,769 shares of the company's stock, valued at approximately $431,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. R Squared Ltd acquired a new position in IDEAYA Biosciences in the 4th quarter valued at about $35,000. Daiwa Securities Group Inc. increased its stake in IDEAYA Biosciences by 44.0% during the 4th quarter. Daiwa Securities Group Inc. now owns 2,792 shares of the company's stock worth $72,000 after buying an additional 853 shares during the period. KBC Group NV lifted its holdings in IDEAYA Biosciences by 84.6% during the 4th quarter. KBC Group NV now owns 4,197 shares of the company's stock worth $108,000 after buying an additional 1,923 shares in the last quarter. Cibc World Markets Corp acquired a new stake in IDEAYA Biosciences in the 4th quarter valued at about $203,000. Finally, Aigen Investment Management LP purchased a new stake in shares of IDEAYA Biosciences during the 4th quarter worth $280,000. Hedge funds and other institutional investors own 98.29% of the company's stock.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on the stock. Royal Bank of Canada restated an "outperform" rating and set a $61.00 price objective on shares of IDEAYA Biosciences in a research report on Wednesday, January 15th. Stephens reiterated an "overweight" rating and set a $50.00 target price on shares of IDEAYA Biosciences in a research note on Friday, February 14th. Finally, Cantor Fitzgerald reissued an "overweight" rating on shares of IDEAYA Biosciences in a research note on Monday, January 13th. Two equities research analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $53.58.

IDEAYA Biosciences Stock Performance

IDEAYA Biosciences stock traded down $0.90 during midday trading on Tuesday, reaching $17.45. 862,899 shares of the company were exchanged, compared to its average volume of 991,391. The firm's 50-day simple moving average is $17.72 and its 200-day simple moving average is $22.51. IDEAYA Biosciences, Inc. has a 1 year low of $13.45 and a 1 year high of $44.42. The company has a market capitalization of $1.53 billion, a price-to-earnings ratio of -5.29 and a beta of 0.26.

IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last announced its quarterly earnings data on Tuesday, May 6th. The company reported ($0.82) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by ($0.07). During the same quarter last year, the firm earned ($0.53) EPS. On average, analysts forecast that IDEAYA Biosciences, Inc. will post -3.07 EPS for the current fiscal year.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.